StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Intellia Therapeutics's price to book ratio was 2.2× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.8× to 7.9×, with a median of 2.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.2×+0.8
2025Dec 31, 20251.4×+0.2
2024Dec 31, 20241.2×−1.4
2023Dec 29, 20232.6×−0.6
2022Dec 30, 20223.2×−4.7
2021Dec 31, 20217.9×−1.8
2020Dec 31, 20209.7×+7.1
2019Dec 31, 20192.6×+0.4
2018Dec 31, 20182.2×−1.7
2017Dec 29, 20173.9×+1.8
2016Dec 30, 20162.2×–

More Intellia Therapeutics figures

See a number that looks wrong?